Lisata Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z
Lisata Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for BOLSTER trial design (Approved).
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| Targeted Therapy Delivered | n/a | n/a | n/a | Public pipeline row |
| Spotlight | n/a | n/a | n/a | Public pipeline row |
| BOLSTER trial design | n/a | n/a | Approved | Public pipeline row |
| Biological/Vaccine: therapeutic autologous dendritic cells. | Kidney Cancer | Vaccine | Phase 1 | Public pipeline row |
| NBS10 | ST Segment Elevation Myocardial Infarction | n/a | Phase 2 | Public pipeline row |
| therapeutic autologous dendritic cells | Melanoma (Skin) | Vaccine | Phase 1 | Phase 2 | Public pipeline row |
| ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study) | Myocardial Ischemia | n/a | n/a | Public pipeline row |
| Auto-CD34+ cells | Chronic Myocardial Ischemia | Refractory Angina Pectoris | Advanced Coronary Heart Disease | n/a | Phase 3 | Public pipeline row |
Estimated cash runway: Runway 6-12 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| NCT00300053 | Phase 2 | COMPLETED | 321 | 2008-03 |
| NCT00014131 | Phase 1 | TERMINATED | 9 | 2009-12 |
| NCT00545610 | n/a | COMPLETED | 150 | 2010-04 |
| NCT00012064 | Phase 1 | Phase 2 | COMPLETED | 56 | 2011-04 |
| NCT01495364 | Phase 2 | COMPLETED | 195 | 2014-06 |
| NCT01508910 | Phase 3 | COMPLETED | 291 | 2015-11 |
| NCT03517176 | Phase 1 | COMPLETED | 30 | 2020-06-19 |
| NCT06592664 | Phase 1 | Phase 2 | WITHDRAWN | n/a | 2035-01 |
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.